X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs STERLING BIOTECH - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA STERLING BIOTECH DISHMAN PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 25.1 -1.8 - View Chart
P/BV x 3.3 0.1 4,785.3% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
STERLING BIOTECH
Dec-13
DISHMAN PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs37411 3,565.7%   
Low Rs1293 3,791.2%   
Sales per share (Unadj.) Rs197.826.8 737.9%  
Earnings per share (Unadj.) Rs21.2-15.0 -141.8%  
Cash flow per share (Unadj.) Rs34.7-5.5 -635.6%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.954.9 327.8%  
Shares outstanding (eoy) m80.69267.87 30.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.30.3 490.7%   
Avg P/E ratio x11.9-0.5 -2,553.9%  
P/CF ratio (eoy) x7.2-1.3 -569.7%  
Price / Book Value ratio x1.40.1 1,104.7%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3061,862 1,090.7%   
No. of employees `0000.81.4 61.2%   
Total wages/salary Rs m5,355547 979.3%   
Avg. sales/employee Rs Th19,252.75,303.3 363.0%   
Avg. wages/employee Rs Th6,459.5403.8 1,599.5%   
Avg. net profit/employee Rs Th2,064.1-2,959.0 -69.8%   
INCOME DATA
Net Sales Rs m15,9617,181 222.3%  
Other income Rs m26543 623.0%   
Total revenues Rs m16,2267,223 224.6%   
Gross profit Rs m4,103947 433.3%  
Depreciation Rs m1,0912,543 42.9%   
Interest Rs m9444,377 21.6%   
Profit before tax Rs m2,334-5,931 -39.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624-1,924 -32.4%   
Profit after tax Rs m1,711-4,007 -42.7%  
Gross profit margin %25.713.2 195.0%  
Effective tax rate %26.732.4 82.4%   
Net profit margin %10.7-55.8 -19.2%  
BALANCE SHEET DATA
Current assets Rs m11,01814,335 76.9%   
Current liabilities Rs m9,51749,809 19.1%   
Net working cap to sales %9.4-494.0 -1.9%  
Current ratio x1.20.3 402.3%  
Inventory Days Days110403 27.4%  
Debtors Days Days35171 20.4%  
Net fixed assets Rs m16,30455,432 29.4%   
Share capital Rs m161268 60.2%   
"Free" reserves Rs m12,90713,935 92.6%   
Net worth Rs m14,51614,701 98.7%   
Long term debt Rs m4,1899,478 44.2%   
Total assets Rs m29,80573,988 40.3%  
Interest coverage x3.5-0.4 -977.9%   
Debt to equity ratio x0.30.6 44.8%  
Sales to assets ratio x0.50.1 551.8%   
Return on assets %8.90.5 1,778.7%  
Return on equity %11.8-27.3 -43.3%  
Return on capital %17.5-6.4 -272.8%  
Exports to sales %24.825.9 95.7%   
Imports to sales %3.70.2 2,199.0%   
Exports (fob) Rs m3,9561,860 212.7%   
Imports (cif) Rs m59612 4,887.7%   
Fx inflow Rs m4,9521,860 266.2%   
Fx outflow Rs m69725 2,799.5%   
Net fx Rs m4,2551,835 231.9%   
CASH FLOW
From Operations Rs m2,7861,719 162.1%  
From Investments Rs m-1,529-3,148 48.6%  
From Financial Activity Rs m-9411,426 -66.0%  
Net Cashflow Rs m316-3 -9,305.9%  

Share Holding

Indian Promoters % 61.4 33.9 181.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 0.0 -  
FIIs % 12.7 9.9 128.3%  
ADR/GDR % 0.0 16.9 -  
Free float % 22.1 39.3 56.2%  
Shareholders   46,261 21,482 215.3%  
Pledged promoter(s) holding % 35.8 55.9 63.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   DR. REDDYS LAB  PIRAMAL ENTERPRISES  NATCO PHARMA  AUROBINDO PHARMA  PFIZER  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; Tata Stocks in Focus(09:30 am)

Asian stock indices are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.13% while the Hang Seng is down 0.54%. The Shanghai Composite is trading down by 0.02%.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS